January 17, 2024
Daiichi Sankyo is discontinuing the marketing of its biosimilar version of the cancer agent Herceptin (trastuzumab) later this year due to the recent shutdown of a third-party manufacturing site used by licensing partner Amgen. The Japanese pharma will stop the...read more